Ebola virus: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 1: Line 1:
==Microbiology==
==Background==

=== Microbiology ===


*Negative-sense single-stranded RNA virus in the [[Filoviridae]] family
*Negative-sense single-stranded RNA virus in the [[Filoviridae]] family
Line 8: Line 10:
**Sudan ebolavirus (SUDV)
**Sudan ebolavirus (SUDV)
**Taï Forest (or Cote d'Ivoire) ebolavirus (TAFV)
**Taï Forest (or Cote d'Ivoire) ebolavirus (TAFV)

=== Epidemiology ===

* Essentially located exclusively in west Africa
* Outbreaks occur where there is food insecurity (with resultant hunting for bush meat), increased population density, and insufficient public health infrastructure


==Clinical Manifestations==
==Clinical Manifestations==


*Incubation period [[Incubation period range::2 to 21 days]] (generally [[Usual incubation period::3 to 13 days]])
*Incubation period [[Incubation period range::2 to 21 days]] (generally [[Usual incubation period::3 to 13 days]])
*Fever, fatigue, myalgias, weakness, and dizziness
*Initially starts as a non-specific influenza-like illness with fever, fatigue, myalgias, weakness, and dizziness
*Followed by multiorgan involvement and hemorrhagic manifestations (30-50%)
*EBOV can persist after resolution of symptoms in privileged sites: the eyes, CNS, male reproductive tract, and mammary glands
*EBOV can persist after resolution of symptoms in privileged sites: the eyes, CNS, male reproductive tract, and mammary glands
*Relapse can occur as uveitis or meningitis
*Relapse can occur as uveitis or meningitis
*Death usually within 6 to 16 days of symptom onset

===Prognosis and Complications===

*40 to 70% mortality, depending mostly on supportive care
*Hiccups associated with increased mortality

== Diagnosis ==

* Ensure to notify the lab before sending samples, and contact Public Health for instructions
** [[Biosafety risk groups|Biosafety level 4 agent]]
* qPCR at the Public Health Laboratory Ontario, but only for Zaire ebolavirus
* Canada's National Microbiology Laboratory does RT-PCR, viral isolation, and serology

== Management ==

* Supportive care alone can decrease mortality to 20-30%
* Monoclonal antibodies
** REGN-EB3 (6% mortality)
** mAb-114 (11% mortality)
** Zmapp (24% mortality)
* Medications
** [[Remdesivir]] (33% mortality)


== Prevention ==
=== Prognosis and Complications ===


* Vaccination with a recombinant vesicular stomatitis virus that has its glycoprotein replaced by Ebola virus glycoprotein
* 33 to 75% mortality, depending mostly on supportive care
** Used in large West African and DRC outbreaks with ring vaccination
** Efficacy 95-100%
** >100,000 doses give


[[Category:Filoviridae]]
[[Category:Filoviridae]]

Revision as of 13:31, 28 August 2020

Background

Microbiology

  • Negative-sense single-stranded RNA virus in the Filoviridae family
  • The ebolavirus genus includes five species:
    • Zaire ebolavirus (EBOV), the most common
    • Bundibugyo ebolavirus (BDBV)
    • Reston ebolavirus (RESTV)
    • Sudan ebolavirus (SUDV)
    • Taï Forest (or Cote d'Ivoire) ebolavirus (TAFV)

Epidemiology

  • Essentially located exclusively in west Africa
  • Outbreaks occur where there is food insecurity (with resultant hunting for bush meat), increased population density, and insufficient public health infrastructure

Clinical Manifestations

  • Incubation period 2 to 21 days (generally 3 to 13 days)
  • Initially starts as a non-specific influenza-like illness with fever, fatigue, myalgias, weakness, and dizziness
  • Followed by multiorgan involvement and hemorrhagic manifestations (30-50%)
  • EBOV can persist after resolution of symptoms in privileged sites: the eyes, CNS, male reproductive tract, and mammary glands
  • Relapse can occur as uveitis or meningitis
  • Death usually within 6 to 16 days of symptom onset

Prognosis and Complications

  • 40 to 70% mortality, depending mostly on supportive care
  • Hiccups associated with increased mortality

Diagnosis

  • Ensure to notify the lab before sending samples, and contact Public Health for instructions
  • qPCR at the Public Health Laboratory Ontario, but only for Zaire ebolavirus
  • Canada's National Microbiology Laboratory does RT-PCR, viral isolation, and serology

Management

  • Supportive care alone can decrease mortality to 20-30%
  • Monoclonal antibodies
    • REGN-EB3 (6% mortality)
    • mAb-114 (11% mortality)
    • Zmapp (24% mortality)
  • Medications

Prevention

  • Vaccination with a recombinant vesicular stomatitis virus that has its glycoprotein replaced by Ebola virus glycoprotein
    • Used in large West African and DRC outbreaks with ring vaccination
    • Efficacy 95-100%
    • >100,000 doses give